Immuneering Corporation (IMRX) Free cash flow
- Free cash flow · 12 months (USD): Value $-56.99M; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $-56.99M | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. $-56.75M − $238.46K ≈ $-56.99M |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | (m) | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-56.75M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 0.99× | Operating cash flow / net income. Period ending 2026-06-30. $-56.75M ÷ $-57.28M ≈ 0.99× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -56.75M USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | 238.46K USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | -56.99M USD | Net Cash Provided by (Used in) Operating Activities · Payments to Acquire Property, Plant, and Equipment |
| Revenue | (m) | |
| Quarter-end shares | (m) | |
| Net income | -57.28M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $-56.99M | (m) | $-56.75M | $238.46K | (m) | (m) | (m) | $-57.28M | (m) | (m) | (m) | 0.99× |
| 2026-03-31 | $-49.91M | (m) | $-49.70M | $213.21K | (m) | (m) | (m) | $-54.44M | (m) | (m) | (m) | 0.91× |
| 2025-12-31 | $-45.49M | (m) | $-45.34M | $142.23K | (m) | (m) | (m) | $-56.02M | (m) | (m) | (m) | 0.81× |
| 2025-09-30 | $-50.04M | (m) | $-50.01M | $27.67K | (m) | (m) | (m) | $-62.50M | (m) | (m) | (m) | 0.80× |
| 2025-06-30 | $-51.53M | (m) | $-51.51M | $25.68K | (m) | (m) | (m) | $-62.13M | (m) | (m) | (m) | 0.83× |
| 2025-03-31 | $-53.65M | (m) | $-53.59M | $56.34K | (m) | (m) | (m) | $-61.77M | (m) | (m) | (m) | 0.87× |
| 2024-12-31 | $-55.08M | (m) | $-55.00M | $84.88K | (m) | (m) | (m) | $-61.04M | (m) | (m) | (m) | 0.90× |
| 2024-09-30 | $-52.51M | (m) | $-52.26M | $246.44K | (m) | (m) | (m) | $-58.07M | (m) | (m) | (m) | 0.90× |
| 2024-06-30 | $-51.12M | (m) | $-50.82M | $298.32K | (m) | (m) | (m) | $-56.07M | (m) | (m) | (m) | 0.91× |
| 2024-03-31 | $-50.39M | (m) | $-50.04M | $352.23K | (m) | (m) | (m) | $-54.18M | (m) | (m) | (m) | 0.92× |
| 2023-12-31 | $-49.31M | (m) | $-48.97M | $342.75K | (m) | $0.00 | (m) | $-53.47M | (m) | (m) | (m) | 0.92× |
| 2023-09-30 | $-49.18M | (m) | $-48.94M | $241.13K | (m) | $455.00 | (m) | $-51.63M | (m) | (m) | -10809489.45% | 0.95× |
| 2023-06-30 | $-48.11M | (m) | $-47.54M | $577.12K | (m) | $38.84K | (m) | $-51.88M | (m) | (m) | -123894.86% | 0.92× |
| 2023-03-31 | $-46.89M | (m) | $-46.24M | $655.43K | (m) | $133.25K | (m) | $-51.22M | (m) | (m) | -35191.19% | 0.90× |
| 2022-12-31 | $-44.84M | (m) | $-44.10M | $742.48K | (m) | $316.95K | (m) | $-50.51M | (m) | (m) | -14148.44% | 0.87× |
| 2022-09-30 | $-42.28M | (m) | $-41.59M | $686.23K | (m) | $506.09K | (m) | $-48.05M | (m) | (m) | -8353.86% | 0.87× |
| 2022-06-30 | $-40.31M | (m) | $-40.00M | $304.44K | (m) | $949.84K | (m) | $-43.74M | (m) | (m) | -4243.71% | 0.91× |
| 2022-03-31 | $-37.15M | (m) | $-36.99M | $159.27K | (m) | $1.52M | (m) | $-40.20M | (m) | (m) | -2451.49% | 0.92× |
| 2021-12-31 | $-30.91M | (m) | $-30.85M | $60.79K | (m) | $2.08M | (m) | $-33.54M | (m) | (m) | -1486.17% | 0.92× |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $-20.07M | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-14.67M | (m) | $-14.62M | $53.41K | (m) | $2.31M | (m) | $-17.04M | (m) | (m) | -634.83% | 0.86× |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |